Therapies in development for non-infectious uveitis

M. A. Sadiq, A. Agarwal, M. Hassan, R. Afridi, S. Sarwar, M. K. Soliman, D. V. Do, Q. D. Nguyen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Uveitis represents a spectrum of diseases characterized by ocular inflammation that leads to significant visual loss if left untreated. Adequate, long-term control of inflammation with minimal systemic and local adverse effects is the preferred strategy for treating patients with uveitis. Pharmacotherapy for uveitis consists mainly of corticosteroids in various formulations such as topical, local, intraocular and systemic. However, monotherapy with corticosteroids is often unacceptable due to serious adverse effects on various organ systems. There exist limitations with the use of steroid-sparing systemic immunosuppressive agents, as these medications may have significant adverse events and a narrow therapeutic window. Thus, newer molecular targets that act on various steps of the inflammatory pathway appear to be promising emerging strategies for treating uveitis. Specially designed monoclonal antibodies in development can potentially halt the inflammatory processes resulting in remission of the disease. In the index review, novel molecular agents and biological therapies that have shown promising efficacy and safety data in preclinical and clinical studies have been summarized. In addition, new drug delivery systems that may ensure high intraocular therapeutic levels of pharmacologic agents have been highlighted.

Original languageEnglish (US)
Pages (from-to)565-577
Number of pages13
JournalCurrent Molecular Medicine
Volume15
Issue number6
DOIs
StatePublished - Aug 1 2015

Fingerprint

Uveitis
Adrenal Cortex Hormones
Drug therapy
Immunosuppressive Agents
Steroids
Monoclonal Antibodies
Inflammation
Biological Therapy
Therapeutics
Drug Delivery Systems
Safety
Drug Therapy

Keywords

  • Drug-delivery systems
  • Immunomodulatory therapy
  • Non-infectious
  • Treatment
  • Uveitis

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Cite this

Sadiq, M. A., Agarwal, A., Hassan, M., Afridi, R., Sarwar, S., Soliman, M. K., ... Nguyen, Q. D. (2015). Therapies in development for non-infectious uveitis. Current Molecular Medicine, 15(6), 565-577. https://doi.org/10.2174/1566524015666150731103847

Therapies in development for non-infectious uveitis. / Sadiq, M. A.; Agarwal, A.; Hassan, M.; Afridi, R.; Sarwar, S.; Soliman, M. K.; Do, D. V.; Nguyen, Q. D.

In: Current Molecular Medicine, Vol. 15, No. 6, 01.08.2015, p. 565-577.

Research output: Contribution to journalArticle

Sadiq, MA, Agarwal, A, Hassan, M, Afridi, R, Sarwar, S, Soliman, MK, Do, DV & Nguyen, QD 2015, 'Therapies in development for non-infectious uveitis', Current Molecular Medicine, vol. 15, no. 6, pp. 565-577. https://doi.org/10.2174/1566524015666150731103847
Sadiq MA, Agarwal A, Hassan M, Afridi R, Sarwar S, Soliman MK et al. Therapies in development for non-infectious uveitis. Current Molecular Medicine. 2015 Aug 1;15(6):565-577. https://doi.org/10.2174/1566524015666150731103847
Sadiq, M. A. ; Agarwal, A. ; Hassan, M. ; Afridi, R. ; Sarwar, S. ; Soliman, M. K. ; Do, D. V. ; Nguyen, Q. D. / Therapies in development for non-infectious uveitis. In: Current Molecular Medicine. 2015 ; Vol. 15, No. 6. pp. 565-577.
@article{bf8e9e7e1d32413a994034f17df093f3,
title = "Therapies in development for non-infectious uveitis",
abstract = "Uveitis represents a spectrum of diseases characterized by ocular inflammation that leads to significant visual loss if left untreated. Adequate, long-term control of inflammation with minimal systemic and local adverse effects is the preferred strategy for treating patients with uveitis. Pharmacotherapy for uveitis consists mainly of corticosteroids in various formulations such as topical, local, intraocular and systemic. However, monotherapy with corticosteroids is often unacceptable due to serious adverse effects on various organ systems. There exist limitations with the use of steroid-sparing systemic immunosuppressive agents, as these medications may have significant adverse events and a narrow therapeutic window. Thus, newer molecular targets that act on various steps of the inflammatory pathway appear to be promising emerging strategies for treating uveitis. Specially designed monoclonal antibodies in development can potentially halt the inflammatory processes resulting in remission of the disease. In the index review, novel molecular agents and biological therapies that have shown promising efficacy and safety data in preclinical and clinical studies have been summarized. In addition, new drug delivery systems that may ensure high intraocular therapeutic levels of pharmacologic agents have been highlighted.",
keywords = "Drug-delivery systems, Immunomodulatory therapy, Non-infectious, Treatment, Uveitis",
author = "Sadiq, {M. A.} and A. Agarwal and M. Hassan and R. Afridi and S. Sarwar and Soliman, {M. K.} and Do, {D. V.} and Nguyen, {Q. D.}",
year = "2015",
month = "8",
day = "1",
doi = "10.2174/1566524015666150731103847",
language = "English (US)",
volume = "15",
pages = "565--577",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - Therapies in development for non-infectious uveitis

AU - Sadiq, M. A.

AU - Agarwal, A.

AU - Hassan, M.

AU - Afridi, R.

AU - Sarwar, S.

AU - Soliman, M. K.

AU - Do, D. V.

AU - Nguyen, Q. D.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Uveitis represents a spectrum of diseases characterized by ocular inflammation that leads to significant visual loss if left untreated. Adequate, long-term control of inflammation with minimal systemic and local adverse effects is the preferred strategy for treating patients with uveitis. Pharmacotherapy for uveitis consists mainly of corticosteroids in various formulations such as topical, local, intraocular and systemic. However, monotherapy with corticosteroids is often unacceptable due to serious adverse effects on various organ systems. There exist limitations with the use of steroid-sparing systemic immunosuppressive agents, as these medications may have significant adverse events and a narrow therapeutic window. Thus, newer molecular targets that act on various steps of the inflammatory pathway appear to be promising emerging strategies for treating uveitis. Specially designed monoclonal antibodies in development can potentially halt the inflammatory processes resulting in remission of the disease. In the index review, novel molecular agents and biological therapies that have shown promising efficacy and safety data in preclinical and clinical studies have been summarized. In addition, new drug delivery systems that may ensure high intraocular therapeutic levels of pharmacologic agents have been highlighted.

AB - Uveitis represents a spectrum of diseases characterized by ocular inflammation that leads to significant visual loss if left untreated. Adequate, long-term control of inflammation with minimal systemic and local adverse effects is the preferred strategy for treating patients with uveitis. Pharmacotherapy for uveitis consists mainly of corticosteroids in various formulations such as topical, local, intraocular and systemic. However, monotherapy with corticosteroids is often unacceptable due to serious adverse effects on various organ systems. There exist limitations with the use of steroid-sparing systemic immunosuppressive agents, as these medications may have significant adverse events and a narrow therapeutic window. Thus, newer molecular targets that act on various steps of the inflammatory pathway appear to be promising emerging strategies for treating uveitis. Specially designed monoclonal antibodies in development can potentially halt the inflammatory processes resulting in remission of the disease. In the index review, novel molecular agents and biological therapies that have shown promising efficacy and safety data in preclinical and clinical studies have been summarized. In addition, new drug delivery systems that may ensure high intraocular therapeutic levels of pharmacologic agents have been highlighted.

KW - Drug-delivery systems

KW - Immunomodulatory therapy

KW - Non-infectious

KW - Treatment

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84940937541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940937541&partnerID=8YFLogxK

U2 - 10.2174/1566524015666150731103847

DO - 10.2174/1566524015666150731103847

M3 - Article

C2 - 26238367

AN - SCOPUS:84940937541

VL - 15

SP - 565

EP - 577

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 6

ER -